Prostate Cancer
Item
patients with pathologically proven prostate cancer
boolean
C0600139 (UMLS CUI [1])
Metastases
Item
no evidence of distant metastases (m0) on physical examination, bone scan
boolean
C0027627 (UMLS CUI [1])
ECOG Performance Status
Item
ecog ps 0,1,2
boolean
C1520224 (UMLS CUI [1])
Organ function
Item
adequate organ function as evidenced by:
boolean
C0678852 (UMLS CUI [1])
Hemoglobin measurement
Item
hemoglobin > 10.0 gm/dl
boolean
C0518015 (UMLS CUI [1])
White Blood Count
Item
white blood count > 3000/mcl
boolean
C0023508 (UMLS CUI [1])
Platelet
Item
platelet count > 90,000/mcl
boolean
C0032181 (UMLS CUI [1])
AST
Item
ast < 2x normal
boolean
C0201899 (UMLS CUI [1])
Age
Item
age > 18 years
boolean
C0001779 (UMLS CUI [1])
Hypersensitivity to leuprolide or goserelin, PSA level, Gleason Score, Tumor Stage
Item
patients can not be allergic to leuprolide or goserelin if the pretreatment psa > 20, gleason score > 8, t3/4, or n1 disease
boolean
C0020517 (UMLS CUI [1,1])
C0085272 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C0120107 (UMLS CUI [2,2])
C0201544 (UMLS CUI [3])
C0332326 (UMLS CUI [4])
C1300072 (UMLS CUI [5])
Informed Consent
Item
written informed consent
boolean
C0021430 (UMLS CUI [1])
Number of enrolled patients
Item
we anticipate enrolling at least 50 patients per year, which would bring accrual to projected total of 100 patients in 2 years
boolean
C0449788 (UMLS CUI [1,1])
C2347180 (UMLS CUI [1,2])